vs
Side-by-side financial comparison of Caledonia Mining Corp Plc (CMCL) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $46.9M, roughly 1.2× Caledonia Mining Corp Plc). Caledonia Mining Corp Plc runs the higher net margin — 7.0% vs -83.0%, a 90.0% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 13.8%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 17.1%).
Hochschild Mining plc is a leading British-based silver and gold mining business operating in North, Central, and South America. It is headquartered in Lima, Peru, with a corporate office in London, is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index. The main shareholder is the Peruvian businessman Eduardo Hochschild.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
CMCL vs RYTM — Head-to-Head
Income Statement — Q3 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $46.9M | $57.3M |
| Net Profit | $3.3M | $-47.5M |
| Gross Margin | 41.2% | 91.6% |
| Operating Margin | 18.6% | -82.2% |
| Net Margin | 7.0% | -83.0% |
| Revenue YoY | 13.8% | 36.9% |
| Net Profit YoY | -33.3% | -9.6% |
| EPS (diluted) | $0.13 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $57.3M | ||
| Q3 25 | — | $51.3M | ||
| Q2 25 | — | $48.5M | ||
| Q1 25 | — | $32.7M | ||
| Q4 24 | — | $41.8M | ||
| Q3 24 | $46.9M | $33.3M | ||
| Q2 24 | $50.1M | $29.1M | ||
| Q1 24 | $38.5M | $26.0M |
| Q4 25 | — | $-47.5M | ||
| Q3 25 | — | $-52.9M | ||
| Q2 25 | — | $-46.6M | ||
| Q1 25 | — | $-49.5M | ||
| Q4 24 | — | $-43.3M | ||
| Q3 24 | $3.3M | $-43.6M | ||
| Q2 24 | $10.2M | $-32.3M | ||
| Q1 24 | $2.1M | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | 41.2% | 88.5% | ||
| Q2 24 | 45.8% | 89.9% | ||
| Q1 24 | 35.9% | 89.2% |
| Q4 25 | — | -82.2% | ||
| Q3 25 | — | -102.6% | ||
| Q2 25 | — | -93.4% | ||
| Q1 25 | — | -143.7% | ||
| Q4 24 | — | -98.6% | ||
| Q3 24 | 18.6% | -132.0% | ||
| Q2 24 | 32.2% | -139.2% | ||
| Q1 24 | 13.8% | -538.7% |
| Q4 25 | — | -83.0% | ||
| Q3 25 | — | -103.1% | ||
| Q2 25 | — | -96.1% | ||
| Q1 25 | — | -151.4% | ||
| Q4 24 | — | -103.6% | ||
| Q3 24 | 7.0% | -131.2% | ||
| Q2 24 | 20.3% | -110.9% | ||
| Q1 24 | 5.4% | -544.4% |
| Q4 25 | — | $-0.73 | ||
| Q3 25 | — | $-0.82 | ||
| Q2 25 | — | $-0.75 | ||
| Q1 25 | — | $-0.81 | ||
| Q4 24 | — | $-0.71 | ||
| Q3 24 | $0.13 | $-0.73 | ||
| Q2 24 | $0.42 | $-0.55 | ||
| Q1 24 | $0.07 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.2M | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $231.0M | $139.1M |
| Total Assets | $339.7M | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $388.9M | ||
| Q3 25 | — | $416.1M | ||
| Q2 25 | — | $291.0M | ||
| Q1 25 | — | $314.5M | ||
| Q4 24 | — | $320.6M | ||
| Q3 24 | $7.2M | $298.4M | ||
| Q2 24 | $15.4M | $319.1M | ||
| Q1 24 | $1.8M | $201.2M |
| Q4 25 | — | $139.1M | ||
| Q3 25 | — | $148.8M | ||
| Q2 25 | — | $-11.9M | ||
| Q1 25 | — | $18.9M | ||
| Q4 24 | — | $21.7M | ||
| Q3 24 | $231.0M | $11.2M | ||
| Q2 24 | $231.1M | $39.3M | ||
| Q1 24 | $220.3M | $61.6M |
| Q4 25 | — | $480.2M | ||
| Q3 25 | — | $506.9M | ||
| Q2 25 | — | $372.7M | ||
| Q1 25 | — | $386.7M | ||
| Q4 24 | — | $392.3M | ||
| Q3 24 | $339.7M | $363.6M | ||
| Q2 24 | $338.5M | $381.8M | ||
| Q1 24 | $321.8M | $258.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.6M | $-25.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.40× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-25.4M | ||
| Q3 25 | — | $-26.6M | ||
| Q2 25 | — | $-23.3M | ||
| Q1 25 | — | $-40.4M | ||
| Q4 24 | — | $-18.8M | ||
| Q3 24 | $4.6M | $-25.2M | ||
| Q2 24 | $19.1M | $-29.1M | ||
| Q1 24 | — | $-40.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.40× | — | ||
| Q2 24 | 1.87× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
